Kestra Medical Technologies, Ltd. (KMTS) AI Stock Analysis

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company based in Kirkland, Washington. Founded in 2014, the company focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. Its Cardiac Recovery System platform offers an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest during recovery periods. This platform includes the ASSURE Wearable Cardioverter Defibrillator, which monitors heart rhythms and delivers defibrillation therapy when life-threatening ventricular arrhythmias occur, alongside digital patient engagement and clinical workflow solutions.

Annual revenue expanded from $7.6M in FY2023 to $27.8M in FY2024, $59.8M in FY2025, and $95.1M in FY2026, marking a 3-year revenue CAGR of 131.9%. Gross margin improved substantially over this period, rising from -139.6% in FY2023 to 1.3% in FY2024, 40.5% in FY2025, and 51.4% in FY2026. However, annual net losses widened from -$84.2M in FY2023 to -$131.6M in FY2026. For the latest quarter ended July 31, 2026, quarterly revenue grew 59.9% year-over-year, bringing trailing twelve months revenue to $106.7M. Over the trailing twelve months, operating margin was -121.6% and profit margin stood at -140.4%.

As of July 31, 2026, Kestra Medical held $198.9M in cash and short-term investments against $76.4M in total debt, resulting in net cash of $122.5M. Total assets stood at $347.4M and shareholders' equity was $222.4M. The company maintains liquidity with a current ratio of 4.69 and a debt-to-equity ratio of 0.34. In FY2026, operating cash flow was -$81.7M and free cash flow was -$116.6M. Cash deployments in FY2026 included $34.9M in capital expenditures, $2.8M in share buybacks, and $323,000 in dividends paid.

At a market capitalization of $1.62B and an enterprise value of $1.40B, Kestra Medical trades at a price-to-sales multiple of 15.2x and an EV-to-revenue multiple of 13.1x. Its price-to-sales ratio stands above the 4.1x median of its US-listed Healthcare peers, while its price-to-book ratio is 6.8x. Over the past year, the stock returned 17.1%, slightly outpacing the S&P 500 return of 16.8%. Year-to-date, the stock has gained 2.7%, closing at $27.24 on October 16, 2026, which sits 15.5% above its 200-day moving average.

Analyst coverage consists of 5 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell recommendations. The mean price target is $30.29, representing an 11.2% upside compared to the last close of $27.24. For the fiscal year ending April 30, 2027, consensus estimates project revenue of $140.9M and an EPS of -$2.45. For the following fiscal year, 2 analysts project revenue of $195.9M and an EPS of -$2.06. Kestra has beaten EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for December 10, 2026.

This page is an AI-written research summary of Kestra Medical Technologies, Ltd. (KMTS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KMTS income statement, KMTS balance sheet, KMTS key metrics, KMTS analyst forecast, KMTS chart. See the KMTS stock overview for the latest quote and news.